Immunopharmacology Comments

RSLV-132 was designed to breakdown extracellular RNA that circulates in the blood of patients with systemic lupus erythematosus [1], and which is associated with pathogenesis in this condition [2-3]. Decreasing blood-bourne RNA is expected to reduce activation of the B cell receptor/Toll-like receptor 7 pathway to bring about a reduction in inflammatory cytokine production.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Systemic lupus erythematosus	Disease Ontology: DOID:9074 OMIM: 152700 Orphanet: ORPHA536	RSLV-132 has progressed to Phase 2 clinical evaluation in SLE patients- see NCT03247686
Sjögren's syndrome	Orphanet: ORPHA378	RSLV-132 has progressed to Phase 2 clinical evaluation in SS patients- see NCT02660944